Research Article
Neutrophil-to-Lymphocyte Ratio (NLR) Predicts PD-1 Inhibitor Survival in Patients with Metastatic Gastric Cancer
Table 3
Univariate analysis and multivariate analysis of progression-free time.
| Variable category | Category | Univariate analysis | Multivariate analysis | HR (95% CI) | value | HR (95% CI) | value |
| Gender | Female versus male | 0.97 (0.64-1.47) | 0.894 | 0.92 (0.556-1.533) | 0.757 | Age | ⩾59 versus <59 | 1.29 (0.88-1.88) | 0.182 | 1.33 (0.83-2.11) | 0.236 | ECOG | ⩾2 versus 0-1 | 1.96 (1.14-3.37) | 0.012 | 2.74 (1.52-4.96) | 0.001 | Tumor_location | Cardia versus body/fundus versus pylorus | 0.89 (0.70-1.10) | 0.114 | 1.07 (0.81-1.40) | 0.636 | Histological_differentiation | Poorly versus moderately and well | 1.44 (0.99-2.08) | 0.051 | 1.54 (1.00-2.37) | 0.049 | No. of metastasis organs | ≥2 versus <2 | 1.40 (0.91-2.17) | 0.119 | 1.24 (0.78-1.97) | 0.370 | Liver metastasis | Yes versus no | 0.99 (0.68-1.45) | 0.966 | 0.96 (0.61-1.49) | 0.847 | Smoking_history | Smoke versus never smoked | 1.39 (0.97-2.02) | 0.072 | 1.37 (0.83-2.27) | 0.223 | Drinking_history | Drink versus never drinked | 0.84 (0.58-1.22) | 0.361 | 0.95 (0.57-1.58) | 0.830 | Anti-PD-1 therapy line | First line versus second line and third line | 0.61 (0.43-0.89) | 0.008 | 0.65 (0.41-1.04) | 0.074 | Treatment type | Anti-PD-1 plus chemotherapy versus anti-PD-1 monotherapy or antiangiogenesis | 0.67 (0.45-0.94) | 0.033 | 1.12 (0.68-1.87) | 0.647 | Baseline NLR | <3.23 versus ≥3.23 | 0.42 (0.29-0.62) | <0.001 | 0.43 (0.29-0.64) | <0.001 |
|
|
CI: confidence interval; ECOG PS: Eastern Cooperative Oncology Group Performance Status; NLR: neutrophil-to-lymphocyte ratio; HR: hazard ratio.
|